Chuanpu Hu to Speak at 3rd Pharmacokinetics and Pharmacodynamics Conference (Oct 24-26, 2012 in PA)

San Diego, California (PressExposure) September 20, 2012 -- Chuanpu Hu, Scientific Director, Pharmacometrics Biologics Clinical Pharmacology at Johnson & Johnson Will Give a Featured Presentation on "Confirmatory Population PK (/PD) Analysis: Faster and More Robust" at the 3rd Pharmacokinetics & Pharmacodynamics Conference (Oct 24-26, 2012 in Philadelphia, PA)

Population PK (/PD) modeling is receiving increasing use in drug development, including potential dosing adjustment and drug labeling. As the best structural and covariate models are unknown, the common practice is to conduct extensive search among all possible models, costing significant time and resources. On the other hand, it has been shown that model searching can cause selection bias. Dr. Chuanpu Hu will discuss a confirmatory approach, which pre-specifies the analysis model using prior information of the compound and the sample size information of the data at hand. Its pros and cons in comparison with the exploratory approach will be discussed in the context of influencing dosing selection and drug labeling. Mitigation strategies of potential concerns will also be discussed.

Benefits to audience:

1. Understand the pros and cons of model searching

2. Recognize how model searching may affect results and interpretation

3. Reduce population modeling workload by up to 50% or more

4. Conduct PK/PD modeling faster, and with more robust results

Chuanpu Hu has over 15 years experience in modeling and simulation, covering the range of regulatory, consulting, large pharma and biologics environments. He spent an early career from 1996 - 2004 at Office of Biostatistics, FDA; Consulting, Pharsight Corp.; and Clinical Pharmacokinetics, GlaxoSmithCline. Since 2004, he has assumed leadership roles in promoting model-based drug development. He led Exploratory Sciences, Biostatics at Sanofi-aventis during 2004 - 2007, and has lead Pharmacometrics at Biologics Clinical Pharmacology, Johnson & Johnson since 2007. Chuanpu Hu has first-authored methodological publications in journals including Journal of Pharmacokinetics and Pharmacodynamics, Journal of Clinical Pharmacology, Pharmaceutical Statistics, and Statistics in Medicine.

The 3rd Pharmacokinetics & Pharmacodynamics Conference is exclusively designed to showcase the state-of-the-art methodologies in the field of PK/PD, which would define the future of the field, and maximize the probability of achieving clinical success for drug companies. Key challenges faced by a PK/PD scientist will be addressed and approaches to overcome the challenges will be demonstrated.

This conference is a part of our 8th Modern Drug Discovery & Development Summit, which includes five concurrent tracks including:

Track: 3rd Pharmacokinetics & Pharmacodynamics

Track: 9th Stem Cell Research & Therapeutics

Track: 7th Assay Development & Drug Discovery

Track: 4th Translational Medicine

Track: Biotechnology Transfers & Commercialization

For more information, please visit

About GTC

GTC organizes conferences specifically for the biomedical and biopharmaceutical industries. Our goal is to facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic and government organizations, and the financial community.

GTC (Global Technology Community), LLC, is a privately held company founded in 2002.

Company Contact:
635 W. Foothill Blvd. Monrovia, CA 91016
Tel: (626) 256-6405
fax: (626) 466-4433

Company Website:

Event Website:

Press Release Source:

Press Release Submitted On: September 20, 2012 at 10:37 pm
This article has been viewed 60279 time(s).